November 2004 |
|
Grassley, Baucus Raise Concerns Over Offer in Compromise Program
|
|
Chairman Grassley questions acting FDA Commissioner about allegations of FDA actions against drug safety official
|
|
Chairman asks for Inspector General review of allegations of FDA effort to discredit hearing witness
|
|
Finance Committee Jurisdiction Over Tax Issues
|
|
Grassley Praises Final Passage of Miscellaneous Tariff Bill
|
|
Grassley Praises New Partnership to Educate Medicare Beneficiaries on New Benefits
|
|
Grassley Expresses Concerns Over European Actions to Reinvigorate Trade Disputes
|
|
Senators Introduce Tax Technical Corrections Bill
|
|
Grassley Confirms Ongoing Monitoring and Clinical Involvement in 75 Percent Rehab Rule
|
|
Grassley Welcomes USTR Announcement of Steps to Advance CAFTA Without Dominican Republic
|
|
Grassley, Baucus to Appropriators: Drop Item That Would Hurt Tax Shelter, Terrorist Financing Crackdown
|
|
Comment on the Pension Benefit Guaranty Corporation’s Financial Statement
|
|
Grassley to Convene Hearing on Worldwide Withdrawal of Vioxx
|
|
Grassley: Federal Government is Too Slow to Cut Wasteful Employee Moves
|
|
Chairman Grassley reacts to the FDA's new drug safety initiatives and asks agency to specify what steps it took in response to knowns risks with Vioxx
|